Dahl ML - Search Results

1

Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.

Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E. Smith RL, et al. Among authors: dahl ml. CNS Drugs. 2017 Nov;31(11):991-997. doi: 10.1007/s40263-017-0469-1. CNS Drugs. 2017. PMID: 28948574

2

No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.

Söderberg MM, Molden E, Dahl ML. Söderberg MM, et al. Among authors: dahl ml. Pharmacogenet Genomics. 2014 May;24(5):272-5. doi: 10.1097/FPC.0000000000000041. Pharmacogenet Genomics. 2014. PMID: 24595013

3

Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.

Söderberg MM, Haslemo T, Molden E, Dahl ML. Söderberg MM, et al. Among authors: dahl ml. Pharmacogenet Genomics. 2013 May;23(5):279-85. doi: 10.1097/FPC.0b013e3283602876. Pharmacogenet Genomics. 2013. PMID: 23492908

4

Therapeutic drug monitoring for tomorrow.

Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML. Eliasson E, et al. Among authors: dahl ml. Eur J Clin Pharmacol. 2013 May;69 Suppl 1:25-32. doi: 10.1007/s00228-013-1504-x. Epub 2013 May 3. Eur J Clin Pharmacol. 2013. PMID: 23640185 Review.

5

Tribute to Folke Sjöqvist, a Pioneer in Clinical Pharmacology.

Dahl ML, Bergman U, Bertilsson L, Eliasson E, Gustafsson LL, Panagiotidis G, Rane A. Dahl ML, et al. Clin Pharmacol Ther. 2020 Dec;108(6):1127-1128. doi: 10.1002/cpt.1935. Epub 2020 Jul 8. Clin Pharmacol Ther. 2020. PMID: 32535883 No abstract available.

6

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl ML. Yasar U, et al. Among authors: dahl ml. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. doi: 10.1067/mcp.2002.121216. Clin Pharmacol Ther. 2002. PMID: 11823761 Clinical Trial.

7

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.

Margolin S, Lindh JD, Thorén L, Xie H, Koukel L, Dahl ML, Eliasson E. Margolin S, et al. Among authors: dahl ml. Pharmacogenomics. 2013 Apr;14(6):613-22. doi: 10.2217/pgs.13.47. Pharmacogenomics. 2013. PMID: 23570465

8

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML. Griskevicius L, et al. Among authors: dahl ml. Eur J Clin Pharmacol. 2003 Jun;59(2):103-9. doi: 10.1007/s00228-003-0590-6. Epub 2003 Apr 9. Eur J Clin Pharmacol. 2003. PMID: 12684728

9

Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.

Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Hedenmalm K, et al. Among authors: dahl ml. J Clin Psychopharmacol. 2006 Apr;26(2):192-7. doi: 10.1097/01.jcp.0000203200.96205.34. J Clin Psychopharmacol. 2006. PMID: 16633151

10

CYP2C9 genetic variants and losartan oxidation in a Turkish population.

Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO, Bozkurt A. Babaoglu MO, et al. Among authors: dahl ml. Eur J Clin Pharmacol. 2004 Jul;60(5):337-42. doi: 10.1007/s00228-004-0785-5. Epub 2004 Jun 10. Eur J Clin Pharmacol. 2004. PMID: 15197523

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page